



Press
release

Montpellier (France), April 30, 2019 - 5:45 pm CET

Intrasense™ and Radboudumc sign a multiyear partnership, deploying Myrian® XP-Prostate application as a worldwide reference

Intrasense™ (FR0011179886 - ALINS), specialist in medical imaging software solutions, and Radboud university medical center, a worldwide specialist in prostate MRI guided biopsy announce the signature of a contract for a large-scale deployment of Myrian® XP-Prostate, one of the clinical applications of the medical imaging company.

Myrian® XP Prostate chosen by a worldwide specialist of prostate cancer diagnosis

In the mid-nineties, Radboudumc has been one of the first medical centers in the world studying prostate cancer by using magnetic resonance imaging (MRI), and has co-developed a structured way of reading the images, the so called 'PI-RADS' system. This method has become the international standard for the diagnosis of prostate cancer and is available on Myrian XP-Prostate clinical module.

Pioneer in this field of diagnostics for prostate cancer, the innovative method developed by Radboudumc is using MRI images and MR-targeted biopsy instead of transrectal ultrasound biopsy, as currently used in most procedures.

This new method allows to reduce the need for prostate biopsy by 50%, where traditionally no pre-biopsy imaging was performed.

With the objective of training radiologists worldwide and developing expert centers based on this new multiparametric MRI prostate method, Radboudumc has established a Prostate MRI Reference Center (PMRC). The PMRC already setup and trained 20 expert centers around the world and has the ambition to grow to more than 100 centers in the coming years.

Myrian® XP Prostate, the new reference tool for worldwide prostate experts

Based on this vision and what has already been accomplished, the Myrian® platform and its XP-Prostate module have been selected by Radboudumc to be



the prostate MRI reading solution deployed worldwide for PMRC the education program and its expert centers.

The solution developed by Intrasense™ uses advanced analysis tools to visualize, characterize and measure prostate MR examinations, and provides a structured organ-based report with a task-based workflow. It will be deployed within the PMRC network of expert centers within the next months and is therefore strengthening its clinical leadership position as the worldwide reference tool. This large-scale cloud-based deployment also demonstrates Myrian® integration capabilities which have been developed over the last months.

This new commercial success for Intrasense™ with a worldwide reference like Radboudumc will provide further recurring business revenues and visibility to the leading medical imaging software company.

About Intrasense™

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

About Radboudumc PMRC

Radboudumc PMRC aims at sharing and implementing Prostate MRI knowledge through education, innovation, and research.

If you are interested to (further) specialize in prostate MRI, you are cordially invited to join the Radboudumc PMRC 4-days Hands-on course in September. In order to register please see: www.prostatemri.org

Contacts

Intrasense
Nicolas Reymond
Chief Executive Officer
1231 avenue du Mondial 98,
34000 Montpellier, FRANCE
Tel: +334 67 130 130
investor@intrasense.fr

NewCap
Investor Relations and Financial
Communication
Valentine Brouchet
Pierre Laurent
Tel: +331 44 71 94 96
intrasense@newcap.eu

